Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women’s Health, Osteoporosis, Progestin, Estrogen (HOPE) trial-Reference-Cited by-同舟云学术

Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women’s Health, Osteoporosis, Progestin, Estrogen (HOPE) trial

Published:2007-08 Issue:2 Volume:197 Page:137.e1-137.e7
ISSN:0002-9378
Container-title:American Journal of Obstetrics and Gynecology
language:en
Short-container-title:American Journal of Obstetrics and Gynecology

Author:

Thorneycroft Ian H.,Lindsay Robert,Pickar James H.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference25 articles.

1. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial;Greendale;Obstet Gynecol,1998

2. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate;Utian;Fertil Steril,2001

3. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial;JAMA,1996

4. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women;Lindsay;JAMA,2002

5. Side effects of hormone replacement therapy and influence on pattern of use among women aged 45-64 years;Bakken;Acta Obstet Gynecol Scand,2004

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial;Menopause;2021-11

2. The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia;Frontiers in Medicine;2021-10-25

3. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice;Human Reproduction Update;2021-08-25

4. Hormonersatztherapie und Prävention gemäß S3-Leitlinie;Der Gynäkologe;2020-02-12

5. Hormonersatztherapie und Prävention gemäß S3-Leitlinie;Gynäkologische Endokrinologie;2020-01-23